Výsledky vyhledávání - "Jean Depamphilis"

Occult hepatitis B virus infection in the setting of hepatitis C virus (HCV) and human immunodeficiency virus (HIV) co-infection: Clinically relevant or a diagnostic problem?

Autor: Ricard Solà, Fiona Smaill, S. Moreno, Maribel Rodriguez-Torres, Norbert Bräu, Jean DePamphilis, J Gonzalez-Garcia, Francesca J. Torriani, Maria C.Maria Mendes-Correa, Juergen K. Rockstroh

Publikováno v: Journal of Medical Virology. 79:694-700

The clinical relevance of occult hepatitis B virus (HBV) infection, defined as detectable HBV DNA serum/liver, in the absence of hepatitis B surface antigen (HBsAg), is unclear. We determined the prevalence of serum occult HBV infection in HIV/HCV co

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::eb122e8b7ce9ef0d07a46d0476086897
https://doi.org/10.1002/jmv.20836

Zobrazit plný text záznamu

Induction dosing of peginterferon alfa-2a (40 KD) and/or high-dose ribavirin in genotype 1 CHC patients with difficult-to-treat characteristics: pharmacokinetic and viral kinetic (PK/VK) assessment from PROGRESS

Autor: Peter N, Morcos, Ruby, Leong, James A, Thommes, Jean, DePamphilis, Joseph F, Grippo, Barbara J, Brennan

Publikováno v: Hepato-gastroenterology. 62(137)

PROGRESS randomized chronic hepatitis C genotype 1 patients with a baseline viral load ≥400,000 IU/mL weighing ≥85 kg to regimens of 180 μg/week for 48 weeks or 360 μg/week for 12 weeks followed by 180 μg/week for 36 weeks peginterferon alfa-2

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::cdf53a173e7800c4e4cd2950cbc882b4
https://pubmed.ncbi.nlm.nih.gov/25911859

Zobrazit plný text záznamu

Efficacy and safety of pegylated (40-kd) interferon α-2a compared with interferon α-2a in noncirrhotic patients with chronic hepatitis C

Autor: Thomas D. Boyer, Mitchell L. Shiffman, Preston P. Purdum, Teresa L. Wright, Simon Pedder, Gregory T. Everson, Jean DePamphilis, Michael W. Fried, Paul J. Pockros, William M. Lee, A. Lin, Robert Reindollar, Donald M. Jensen, K. Rajender Reddy, C. Smith

Publikováno v: Hepatology. 33:433-438

Administration of interferon (IFN) 3 times weekly in patients with chronic hepatitis C (CHC) is associated with low sustained responses, which may be, in part, related to this regimen's inability to maintain IFN concentrations sufficient to suppress

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5e02f47e3ae11393b46126bd23d22357
https://doi.org/10.1053/jhep.2001.21747

Zobrazit plný text záznamu

Virological response is associated with decline in hemoglobin concentration during pegylated interferon and ribavirin therapy in hepatitis C virus genotype 1

Autor: William Sievert, Gregory J. Dore, Geoffrey W. McCaughan, Martin Weltman, B. Rizkalla, Darrell H. G. Crawford, Motoko Yoshihara, William D. Rawlinson, Jean DePamphilis, Stuart K. Roberts, Wendy Cheng

Publikováno v: Hepatology (Baltimore, Md.). 53(4)

Anemia may increase the likelihood of achieving a sustained virological response (SVR) during pegylated interferon and ribavirin treatment of hepatitis C virus (HCV) infection. To determine whether hemoglobin decline is associated with SVR, we retros

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b3fc22f902e2340cb0e9ee0f581999b7
https://pubmed.ncbi.nlm.nih.gov/21520186

Zobrazit plný text záznamu

Degree of viral decline early in treatment predicts sustained virological response in HCV-HIV coinfected patients treated with peginterferon alfa-2a and ribavirin

Autor: Maribel Rodriguez-Torres, Giampiero Carosi, Juergen K. Rockstroh, Francesca J. Torriani, Douglas T. Dieterich, Jean DePamphilis

Publikováno v: HIV clinical trials. 11(1)

In hepatitis C virus (HCV) monoinfection, the on-treatment virological response at Weeks 4 and 12 is a strong predictor of treatment outcomes.In a retrospective analysis, we examined these responses in 289 HIV-HCV coinfected patients treated with Peg

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::46d2786f55d885a8f6dbca1b15356877
https://pubmed.ncbi.nlm.nih.gov/20400406

Zobrazit plný text záznamu

Impact of high-dose peginterferon alfa-2A on virological response rates in patients with hepatitis C genotype 1: a randomized controlled trial

Autor: B. Rizkalla, Paul V. Desmond, Wendy Cheng, Gregory J. Dore, Darrell H. G. Crawford, William Sievert, Martin Weltman, Motoko Yoshihara, William D. Rawlinson, Jean DePamphilis, Geoffrey W. McCaughan, Stuart K. Roberts, Phillipa Marks

Publikováno v: Hepatology (Baltimore, Md.). 50(4)

This study tested the hypothesis that high-dose peginterferon alfa-2a (PEG-IFNalpha-2a) for the first 12 weeks would increase early and sustained virological response (SVR) rates in patients with chronic hepatitis C genotype 1. Eight hundred ninety-s

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a50025c112b266a6be180e9f3e5ea957
https://pubmed.ncbi.nlm.nih.gov/19676125

Zobrazit plný text záznamu

Hepatic steatosis in HIV/HCV co-infected patients: correlates, efficacy and outcomes of anti-HCV therapy: a paired liver biopsy study

Autor: Eduardo Lissen, Peter Buggisch, Janice Main, Maribel Rodriguez-Torres, Nathan Clumeck, Ricard Solà, Douglas T. Dieterich, Mario G. Pessoa, Sugantha Govindarajan, Jean DePamphilis

Publikováno v: Journal of hepatology. 48(5)

Background/Aims Hepatic steatosis is caused by the complex interaction of host and viral factors, such as metabolic syndrome (MS), alcoholism and HCV genotype, and in HIV–HCV co-infected patients, antiretroviral therapy may also play a role. A larg

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::950adf95571f14c9b07c689c089195ad
https://pubmed.ncbi.nlm.nih.gov/18314217

Zobrazit plný text záznamu

Histological response to pegIFNalpha-2a (40KD) plus ribavirin in HIV-hepatitis C virus co-infection

Autor: Julio S. G. Montaner, Mark T. Nelson, Jean DePamphilis, Maria C.Maria Mendes-Correa, Ricardo Sola, Nathan Clumeck, Peter Buggisch, Eduardo Lissen, Janice Main, Mario G. Pessoa, Douglas T. Dieterich

Publikováno v: AIDS (London, England). 20(17)

OBJECTIVE Paired liver biopsies from patients enrolled in the multinational AIDS PEGASYS Ribavirin International Co-infection Trial were analysed to investigate a possible correlation between virological and histological responses. DESIGN AND METHODS

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8ee57f570519b10f9729f8da4fc20886
https://pubmed.ncbi.nlm.nih.gov/17086063

Zobrazit plný text záznamu

Risk factors for hepatic decompensation in patients with HIV/HCV coinfection and liver cirrhosis during interferon-based therapy

Autor: Francesca J. Torriani, Douglas T. Dieterich, Frank Duff, Jonathan Solsky, Sharon Passe, Lisa Cupelli, Stefan Mauss, William Valenti, Jean DePamphilis, Dominique Larrey

Publikováno v: AIDS (London, England). 18(13)

Objective Hepatic decompensation was reported from two recent trials (APRICOT and RIBAVIC) assessing interferon (IFN)-based treatment of hepatitis C virus (HCV) in HIV/HCV-coinfected patients. This paper identifies risk factors associated with hepati

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::52e0eaaab84c451a1635b3f3f4a69db5
https://pubmed.ncbi.nlm.nih.gov/15316334

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání